2020
DOI: 10.1038/s41467-020-18854-2
|View full text |Cite
|
Sign up to set email alerts
|

Two distinct immunopathological profiles in autopsy lungs of COVID-19

Abstract: Coronavirus Disease 19 (COVID-19) is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has grown to a worldwide pandemic with substantial mortality. Immune mediated damage has been proposed as a pathogenic factor, but immune responses in lungs of COVID-19 patients remain poorly characterized. Here we show transcriptomic, histologic and cellular profiles of post mortem COVID-19 (n = 34 tissues from 16 patients) and normal lung tissues (n = 9 tissues from 6 patie… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

22
179
1
11

Year Published

2020
2020
2023
2023

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 240 publications
(222 citation statements)
references
References 52 publications
22
179
1
11
Order By: Relevance
“…Second, given that IL1-β and other pro-inflammatory cytokines are primary targets of monoclonal antibody therapeutics under investigation 36 , these results raise the question of whether further suppression early during the course of the disease may be detrimental in the setting of an already suppressed inflammatory response to SARS-CoV-2. That said, it is important to consider that the attenuation of inflammatory pathways we observed may not hold over the course of the disease, especially in severe cases of COVID-19 where the lower and not upper respiratory tract is the primary site of pathology [37][38][39] . Additional work examining the temporal dynamics of the host response to SARS-CoV-2 in both the upper and lower airways is needed to address these outstanding questions.…”
Section: Discussionmentioning
confidence: 99%
“…Second, given that IL1-β and other pro-inflammatory cytokines are primary targets of monoclonal antibody therapeutics under investigation 36 , these results raise the question of whether further suppression early during the course of the disease may be detrimental in the setting of an already suppressed inflammatory response to SARS-CoV-2. That said, it is important to consider that the attenuation of inflammatory pathways we observed may not hold over the course of the disease, especially in severe cases of COVID-19 where the lower and not upper respiratory tract is the primary site of pathology [37][38][39] . Additional work examining the temporal dynamics of the host response to SARS-CoV-2 in both the upper and lower airways is needed to address these outstanding questions.…”
Section: Discussionmentioning
confidence: 99%
“…Discrepant viral evidence results between qRT-PCR, ISH and IF/IHC technologies have been the subject of several recent studies 60 , 61 , 62 , 63 . The presence of current viral load, the phase of disease course as well as the severity of COVID-19 all have impact on the detection rate of viral RNA or viral protein in a given sample 60 , 61 , 62 , 63 .…”
Section: Discussionmentioning
confidence: 99%
“…In an autopsy series, Nienhold et al describe two “immunopathological reaction patterns” ( 18 ). The first is characterized by lung infiltration of CD8+ PD1+ T cells that they speculate are causing diffuse alveolar damage (DAD) but better viral control, and they question whether the PD-1 positivity denotes exhaustion, but no conclusions are drawn.…”
Section: Discussionmentioning
confidence: 99%
“…The first is characterized by lung infiltration of CD8+ PD1+ T cells that they speculate are causing diffuse alveolar damage (DAD) but better viral control, and they question whether the PD-1 positivity denotes exhaustion, but no conclusions are drawn. The other immunopathological pattern is characterized by significantly higher CD4+ T cell lung infiltrates and a higher viral load ( 18 ). They conclude this suggests CD8+ T cells indeed contribute to viral clearance but may exert a degree of end organ damage ( 18 ).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation